At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed incurable primitive neuroectodermal tumor
- ✓Evidence of progressive or recurrent tumor on MRI within 2 weeks prior to entry
- ✓Must have received and failed prior standard therapy
- ✓Tumor at least 5 mm in size
- ✕Uncontrolled hypertension
- ✕Severe heart disease or history of congestive heart failure
- ✕History of renal conditions that contraindicate high sodium dosages
- ✕History of cardiovascular conditions that contraindicate high sodium dosages
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 In Children With Primitive Neuroectodermal Tumors
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Childhood CNS Primitive Neuroectodermal Tumor. Completed, enrolled 13 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for children with primitive neuroectodermal tumors that have not responded to standard therapy provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with primitive neuroectodermal tumors that have not responded to standard therapy. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children (\> 6 months of age) with primitive neuroectodermal tumors that has not responded to standard therapy.
Study Details
Timeline
Interventions
Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).